OGEN - Oragenics Inc Stock Price, Fair Value and News

1.04USD+0.03 (+2.97%)Delayed as of 30 Apr 2024, 01:41 pm ET

Market Summary

USD1.04+0.03

Delayedas of 30 Apr 2024, 01:41 pm

2.97%

OGEN Stock Price

View Fullscreen

OGEN RSI Chart

OGEN Valuation

Market Cap

4.5M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

120.19

EV/EBITDA

-0.05

Price/Free Cashflow

-0.62

OGEN Price/Sales (Trailing)

OGEN Profitability

EBT Margin

-54858.14%

Return on Equity

-651.98%

Return on Assets

-415.92%

Free Cashflow Yield

-161.11%

OGEN Fundamentals

OGEN Revenue

Revenue (TTM)

37.7K

Rev. Growth (Yr)

-91.32%

Rev. Growth (Qtr)

-43.28%

OGEN Earnings

Earnings (TTM)

-20.7M

Earnings Growth (Yr)

-469.66%

Earnings Growth (Qtr)

-533.29%

Breaking Down OGEN Revenue

52 Week Range

1.024.48

(Low)(High)

Last 7 days

-4.7%

Last 30 days

-29.9%

Last 90 days

-70.9%

Trailing 12 Months

-63.9%

How does OGEN drawdown profile look like?

OGEN Financial Health

Current Ratio

2.15

OGEN Investor Care

Buy Backs (1Y)

97.37%

Diluted EPS (TTM)

-8.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	133.5K	116.2K	37.7K	37.7K
2022	98.1K	109.3K	120.4K	131.5K
2021	0	0	0	87.0K
2020	827.5K	580.7K	333.8K	0
2016	1.1M	0	0	0
2015	1.1M	1.0M	1.2M	1.2M
2014	1.1M	1.2M	1.2M	939.9K
2013	1.1M	1.0M	1.0M	1.0M
2012	1.5M	1.4M	1.3M	1.3M
2011	1.3M	1.4M	1.4M	1.4M
2010	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oragenics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 30, 2023	telling fred	sold	-12,488	3.5681	-3,500	-
Aug 08, 2023	koski robert c	acquired	-	-	25,000	-
Aug 08, 2023	huffman janet	acquired	-	-	15,000	cfo, secretary and treasurer
Aug 08, 2023	murphy kimberly m	acquired	-	-	25,000	ceo and president
Aug 08, 2023	telling fred	acquired	-	-	25,000	-
Aug 08, 2023	dunton alan w	acquired	-	-	25,000	-
Aug 08, 2023	pope charles l	acquired	-	-	25,000	-
Dec 30, 2022	koski robert c	sold	-4,468	0.1055	-42,357	-
Dec 29, 2022	koski robert c	sold	-3,884	0.106	-36,648	-

Which funds bought or sold OGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	WOLFF WIESE MAGANA LLC	added	294	1.00	97.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	300	636	-%
Feb 14, 2024	Team Financial Group, LLC	unchanged	-	3.00	6.00	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	52,613	111,446	-%
Feb 13, 2024	MORGAN STANLEY	new	-	23.00	23.00	-%
Feb 13, 2024	FMR LLC	reduced	-0.19	6,884	14,612	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	reduced	-36.99	1,721	10,616	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	58,833	124,612	-%
Feb 13, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	6.00	6.00	-%

Are Funds Buying or Selling OGEN?

Are funds buying OGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OGEN

No. of Funds

Unveiling Oragenics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	lind global fund ii lp	5.9%	265,000	SC 13G
Feb 12, 2024	odyssey health, inc.	16.6%	511,308	SC 13D
Jan 29, 2021	intracoastal capital, llc	1.6%	1,491,667	SC 13G/A
Jan 26, 2021	hernandez joseph	0%	0	SC 13D/A
Oct 08, 2020	kirk randal j	0.4%	230,792	SC 13D/A
May 15, 2020	hernandez joseph	16.6%	9,200,000	SC 13D
Mar 02, 2020	kirk randal j	9.9%	4,612,166	SC 13D/A
Feb 14, 2020	anson funds management lp	4.9%	2,422,511	SC 13G/A
Feb 11, 2020	intracoastal capital, llc	6.7%	3,333,334	SC 13G/A
Feb 10, 2020	cvi investments, inc.	4.9%	2,422,511	SC 13G/A

Recent SEC filings of Oragenics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 06, 2024	SC 13G	Major Ownership Report
Mar 01, 2024	8-K	Current Report
Feb 29, 2024	424B5	Prospectus Filed
Feb 28, 2024	8-K	Current Report
Feb 28, 2024	8-K	Current Report
Feb 27, 2024	424B5	Prospectus Filed

Peers (Alternatives to Oragenics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Oragenics Inc News

Latest updates

Oragenics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q3	2020Q2	2020Q1	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1
Revenue	-100.0%	-	7,466	13,163	17,024	-	86,047	30,391	15,083	64,518	113,953	163,388	212,823	262,258	240,234	329,795	242,038	363,774	220,504	201,010	303,752	214,660
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	172,304	-97,888	-	-	195,777	129,983	127,299	178,147	134,900
Operating Expenses	508.8%	12,796,324	2,101,912	3,122,481	2,921,839	2,299,412	3,992,566	3,634,856	4,625,210	2,388,102	4,508,367	12,352,306	5,231,762	-	-	-	-	-	-	-	-	-
S&GA Expenses	31.7%	1,754,343	1,332,562	1,115,785	1,249,263	887,734	1,215,498	1,044,334	1,331,549	1,077,758	1,010,006	808,333	1,519,083	-	-	-	-	-	-	-	-	-
R&D Expenses	1335.2%	11,041,982	769,350	2,006,696	1,672,576	1,411,923	2,777,068	2,590,032	3,293,661	1,310,344	3,498,361	11,543,973	3,712,679	-	-	-	-	-	-	-	-	-
EBITDA Margin	-104.3%	-547	-267	-102	-93.51	-108	-118	-135	-153	-179	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-13.7%	12,231	14,170	843	3,347	5,813	5,228	816	3,246	5,102	3,885	885	1,708	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-533.3%	-12,747,429	-2,012,885	-3,050,586	-2,844,837	-2,237,740	-3,870,113	-3,589,543	-4,590,993	-2,292,576	-4,496,560	-12,337,296	-5,187,760	-	-	-	-	-	-	-	-	-
EBT Margin	-103.6%	-548	-269	-103	-93.98	-108	-119	-135	-153	-180	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-533.3%	-12,747,429	-2,012,885	-3,050,586	-2,844,837	-2,237,740	-3,870,113	-3,589,543	-4,590,993	-2,292,576	-4,496,560	-12,337,296	-5,187,760	-	-	-	-	-	-	-	-	-
Net Income Margin	-103.6%	-548	-269	-103	-93.98	-108	-119	-135	-153	-180	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	26.6%	-1,105,983	-1,506,450	-2,580,066	-2,112,133	-2,436,274	-3,812,924	-3,382,805	-5,723,999	-2,504,347	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-37.1%	5.00	8.00	8.00	12.00	15.00	17.00	20.00	24.00	28.00	31.00	35.00	37.00	19.00	11.00	11.00	16.00	20.00	24.00	27.00	31.00	22.00
Current Assets	-50.5%	4.00	8.00	8.00	12.00	14.00	17.00	20.00	23.00	28.00	31.00	35.00	37.00	18.00	11.00	10.00	15.00	19.00	23.00	26.00	31.00	22.00
Cash Equivalents	-39.6%	3.00	6.00	6.00	9.00	11.00	14.00	18.00	21.00	27.00	30.00	35.00	37.00	18.00	10.00	10.00	14.00	18.00	22.00	26.00	29.00	20.00
Net PPE	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	28.2%	2.00	1.00	1.00	2.00	2.00	2.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	1.00
Shareholder's Equity	-51.2%	3.00	6.00	7.00	10.00	13.00	15.00	19.00	22.00	26.00	29.00	33.00	36.00	17.00	10.00	9.00	13.00	17.00	21.00	24.00	29.00	21.00
Retained Earnings	-6.6%	-206	-193	-191	-188	-185	-183	-179	-175	-171	-168	-164	-160	-154	-150	-145	-133	-127	-123	-119	-115	-111
Additional Paid-In Capital	4.7%	208	198	197	197	197	197	195	195	195	195	195	194	164	152	147	139	138	138	138	138	126
Shares Outstanding	19.9%	3.00	3.00	2.00	-	117	-	116	-	2.00	-	116	103	-	-	-	-	-	-	-	-	-
Float	-	-	-	7.00	-	-	-	42.00	-	-	-	81.00	-	-	-	37.00	-	-	-	22.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	26.6%	-1,102	-1,503	-2,576	-2,108	-2,432	-3,775	-3,382	-5,636	-2,484	-4,579	-2,078	-4,327	-3,631	-4,665	-4,832	-3,822	-3,936	-3,377	-3,487	-2,210	-2,977
Share Based Compensation	90.8%	532	279	64.00	80.00	-798.50*	279	279	90.00	232	101	231	1,124	274	195	157	865	10.00	232	165	146	147
Cashflow From Investing	-Infinity%	-1,000	-	-	-	-3.44	-37.03	-	-75.05	-19.75	-	-	-	-	-	-	-	-13.86	-	-	-	-64.48
Cashflow From Financing	-124.7%	-180	732	-107	-159	-87.99	-103	-122	-181	-178	-21.91	152	23,189	11,228	5,080	90.00	-73.02	-73.56	-50.00	-130	11,351	9,439

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OGEN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Grant revenue	$ 37,653	$ 131,521
Operating expenses:
Research and development	15,490,604	10,072,684
General and administrative	5,451,952	4,479,605
Total operating expenses	20,942,556	14,552,289
Loss from operations	(20,904,903)	(14,420,768)
Other income (expense):
Interest income	210,394	135,900
Interest expense	(30,591)	(15,103)
Miscellaneous income	69,363	11,582
Total other income, net	249,166	132,379
Loss before income taxes	(20,655,737)	(14,288,389)
Income tax benefit
Net loss	$ (20,655,737)	$ (14,288,389)
Basic net loss per share	$ (9.18)	$ (7.11)
Diluted net loss per share	$ (9.18)	$ (7.11)
Shares used to compute basic net loss per share	2,249,694	2,009,234
Shares used to compute diluted net loss per share	2,249,694	2,009,234

OGEN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,483,501	$ 11,426,785
Prepaid expenses and other current assets	382,273	2,862,738
Total current assets	3,865,774	14,289,523
Property and equipment, net	(0)	121,062
Prepaid research and development expense	1,090,750	(0)
Operating lease right-of-use assets	9,811	347,440
Total assets	4,966,335	14,758,025
Current liabilities:
Accounts payable and accrued expenses	1,475,667	1,124,197
Short-term notes payable	312,703	267,640
Operating lease liabilities - Current	9,811	204,447
Total current liabilities	1,798,181	1,596,284
Long-term liabilities:
Operating lease liabilities - Long Term		152,439
Total long-term liabilities		152,439
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000 and 5,417,000 Series A shares, 4,050,000 and 4,050,000 Series B shares, -0- and -0- Series C shares, 7,488,197 and -0- Series F shares outstanding at December 31, 2023 and December 31, 2022, respectively	1,592,723	1,592,723
Common stock, $0.001 par value; 350,000,000 shares authorized; 3,080,693 and 2,024,657 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	3,081	2,025
Additional paid-in capital	207,790,604	196,977,071
Accumulated Deficit	(206,218,254)	(185,562,517)
Total shareholders’ equity	3,168,154	13,009,302
Total liabilities and shareholders’ equity	$ 4,966,335	$ 14,758,025

About Oragenics Inc

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

CEO	Ms. Kimberly M. Murphy
WEBSITE	oragenics.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Oragenics Inc Frequently Asked Questions

What is the ticker symbol for Oragenics Inc? What does OGEN stand for in stocks?

OGEN is the stock ticker symbol of Oragenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oragenics Inc (OGEN)?

As of Mon Apr 29 2024, market cap of Oragenics Inc is 4.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OGEN stock?

You can check OGEN's fair value in chart for subscribers.

What is the fair value of OGEN stock?

You can check OGEN's fair value in chart for subscribers. The fair value of Oragenics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oragenics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oragenics Inc a good stock to buy?

The fair value guage provides a quick view whether OGEN is over valued or under valued. Whether Oragenics Inc is cheap or expensive depends on the assumptions which impact Oragenics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OGEN.

What is Oragenics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, OGEN's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 120.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oragenics Inc's stock?

In the past 10 years, Oragenics Inc has provided -0.507 (multiply by 100 for percentage) rate of return.